Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine + bevacizumab with or without vinorelbine for first-line treatment of HER2-negative metastatic or locally advanced inoperable breast cancer
2008-003779-37Phase 2Completed
- Sponsor
- iOMEDICO
- Start
- Oct 2008
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in breast cancer comparing Capecitabine + bevacizumab with Capecitabine + bevacizumab + vinorelbine (2 arms). Primary endpoint: Progression of disease. Started Oct 2008; status: completed.
02
Drugs
capecitabinebevacizumabvinorelbine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-003779-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003779-37.